B7-1 Protein, Human, Recombinant

B7-1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.5 kDa and the accession number is A0N0P2.

B7-1 Protein, Human, Recombinant

パッケージサイズ	在庫状況	単価(税別)
100 μg	在庫あり	￥ 103,500
200 μg	約5 days	￥ 177,000
500 μg	約5 days	￥ 358,000

バルクのお問い合わせ

生物学的情報	Testing in progress
説明	B7-1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.5 kDa and the accession number is A0N0P2.

Species	Human
Expression Host	HEK293 Cells
Tag	Tag Free
Accession Number	A0N0P2
別名	CD28LG1, B7, CD80 molecule, LAB7, B7.1, B7-1, CD28LG, BB1
Construction	The mature form of Human B7-1 (NP_005182.1) extracellular domain (Met 1-Asn 242) with five amini acids (DDDDK) at the C-terminus was expressed and purified.
Protein Purity	> 85 % as determined by SDS-PAGE
分子量	25.5 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

参考文献

1. Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418. 2. Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9. 3. Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

B7-1 Protein, Human, Recombinant

参考文献

Calculator

技術サポート

Keywords